Correlation Between 23Andme Holding and Supernus Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both 23Andme Holding and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 23Andme Holding and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 23Andme Holding Co and Supernus Pharmaceuticals, you can compare the effects of market volatilities on 23Andme Holding and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 23Andme Holding with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of 23Andme Holding and Supernus Pharmaceuticals.
Diversification Opportunities for 23Andme Holding and Supernus Pharmaceuticals
-0.83 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between 23Andme and Supernus is -0.83. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and 23Andme Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 23Andme Holding Co are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of 23Andme Holding i.e., 23Andme Holding and Supernus Pharmaceuticals go up and down completely randomly.
Pair Corralation between 23Andme Holding and Supernus Pharmaceuticals
Allowing for the 90-day total investment horizon 23Andme Holding Co is expected to generate 4.82 times more return on investment than Supernus Pharmaceuticals. However, 23Andme Holding is 4.82 times more volatile than Supernus Pharmaceuticals. It trades about -0.01 of its potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about -0.05 per unit of risk. If you would invest 329.00 in 23Andme Holding Co on September 26, 2024 and sell it today you would lose (12.00) from holding 23Andme Holding Co or give up 3.65% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
23Andme Holding Co vs. Supernus Pharmaceuticals
Performance |
Timeline |
23Andme Holding |
Supernus Pharmaceuticals |
23Andme Holding and Supernus Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with 23Andme Holding and Supernus Pharmaceuticals
The main advantage of trading using opposite 23Andme Holding and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 23Andme Holding position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.23Andme Holding vs. IDEXX Laboratories | 23Andme Holding vs. Twist Bioscience Corp | 23Andme Holding vs. Guardant Health | 23Andme Holding vs. Agilent Technologies |
Supernus Pharmaceuticals vs. Prestige Brand Holdings | Supernus Pharmaceuticals vs. Evotec SE ADR | Supernus Pharmaceuticals vs. Collegium Pharmaceutical | Supernus Pharmaceuticals vs. ANI Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |